Home » Healthcare » Colorectal Cancer Screening and Diagnostic Market

Colorectal Cancer Screening and Diagnostic Market By Type (Stool-based, Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), Stool-DNA Test, Colonoscopy, Others); By End-user (Hospitals & Clinics, Clinical Laboratories, Diagnostics Imaging Centers, Others); By Region – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Price: $4999

Published: | Report ID: 35780 | Report Format : PDF
REPORT ATTRIBUTE DETAILS
Historical Period  2019-2022
Base Year  2023
Forecast Period  2024-2032
Colorectal Cancer Screening and Diagnostic Market Size 2023  USD 15,967.68 million
Colorectal Cancer Screening and Diagnostic Market, CAGR  8.83%
Colorectal Cancer Screening and Diagnostic Market Size 2032  USD 31,702.6 million

Market Overview

The Colorectal Cancer Screening and Diagnostic Market is projected to experience substantial growth, with its value expected to surge from USD 15,967.68 million in 2023 to USD 31,702.6 million by 2032, reflecting a notable CAGR of 8.83%. Colorectal cancer stands as one of the most prevalent and fatal forms of cancer globally, necessitating effective screening and diagnostic measures. The Colorectal Cancer Screening and Diagnostic Market offers a diverse range of products and services aimed at early detection, accurate diagnosis, and treatment monitoring of this malignancy. Market dynamics are chiefly influenced by the increasing global incidence of colorectal cancer, driven by factors such as aging populations, sedentary lifestyles, and dietary habits. Additionally, growing awareness campaigns and government initiatives promoting early detection have spurred market growth.

Advancements in screening technologies and diagnostic modalities have revolutionized colorectal cancer management, with innovations like non-invasive screening tests, molecular diagnostics, and imaging techniques enhancing accuracy and patient comfort. Despite these advancements, challenges such as the high cost of advanced screening tests and lack of awareness in certain regions hinder market progression. The market is segmented based on product type, screening method, and end-user, encompassing a wide array of screening and diagnostic tools catering to hospitals, diagnostic laboratories, ambulatory surgical centers, and research institutes.

Regional analysis reveals variations influenced by healthcare infrastructure, reimbursement policies, and awareness levels. North America dominates the market due to its high prevalence of colorectal cancer and widespread adoption of advanced screening technologies. Europe follows suit, propelled by initiatives promoting early detection and favorable reimbursement policies. The Asia Pacific region presents lucrative growth opportunities driven by increasing cancer incidence, improving healthcare infrastructure, and rising healthcare expenditure.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

CTA Design Element 3

Segmentation Analysis

By Type:

Stool-based tests represent a significant segment within the Colorectal Cancer Screening and Diagnostic Market. This category includes the Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), and Stool-DNA Test. These non-invasive tests offer convenient options for early detection of colorectal cancer by detecting blood or genetic markers in the stool samples. Colonoscopy stands as a cornerstone in the diagnosis and screening of colorectal cancer. This invasive procedure allows for direct visualization of the colon and rectum, enabling the detection of precancerous polyps and early-stage tumors. Despite its invasiveness, colonoscopy offers the advantage of simultaneous biopsy and polyp removal, contributing to its role in both screening and therapeutic interventions.

By End-user:

Hospitals & Clinics constitute a primary end-user segment in the Colorectal Cancer Screening and Diagnostic Market. These healthcare facilities serve as central hubs for patient care, offering a wide range of screening and diagnostic services. Clinical Laboratories play a crucial role in the processing and analysis of screening tests and diagnostic samples. These laboratories utilize specialized equipment and trained personnel to perform various tests, including stool-based assays and molecular diagnostics. Diagnostics Imaging Centers offer essential services for imaging-based screening and diagnostic procedures. These centers utilize advanced imaging technologies such as CT scans and MRI to visualize the colon and identify suspicious lesions or abnormalities.

Segments:

By Type:

  • Stool-based
  • Fecal Immunochemical Test (FIT)
  • Fecal Occult Blood Test (FOBT)
  • Stool-DNA Test
  • Colonoscopy
  • Others

By End-user:

  • Hospitals & Clinics
  • Clinical Laboratories
  • Diagnostics Imaging Centers
  • Others

By Region:

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • The U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of the Middle East and Africa

Market Drivers

Lack of Standardized Data Formats

The absence of universally adopted data exchange formats across healthcare systems creates compatibility issues and hinders seamless data flow. For instance, different vendors and providers often use proprietary formats, making it difficult for their systems to “talk” to each other. This lack of standardization leads to interoperability challenges, impeding the efficient exchange of patient data crucial for coordinated care and decision-making. In 2021, more than 6 in 10 hospitals engaged in key aspects of electronically sharing health information (send, receive, query) and integrating of summary of care records into EHRs, a 51 percent increase since 2017. Healthcare organizations face the daunting task of navigating diverse data formats, resulting in inefficiencies and delays in accessing critical information.

High Implementation Costs

Implementing and maintaining interoperability solutions can be expensive for healthcare providers, especially smaller institutions with limited budgets. Costs associated with hardware, software, training, and ongoing IT support can be a significant barrier to adoption. Healthcare organizations must allocate substantial resources to implement interoperability solutions effectively, diverting funds from other essential initiatives. Moreover, the complexity of interoperability projects amplifies the financial burden, requiring comprehensive investment planning and budget allocation.

Data Security and Privacy Concerns

Sharing sensitive patient data electronically raises concerns about data breaches, unauthorized access, and potential misuse of information. Stringent regulations like HIPAA add complexity to data exchange and require robust security measures, further increasing costs.The fear of data breaches and regulatory non-compliance complicates interoperability initiatives, necessitating stringent risk mitigation strategies and compliance measures.

 Resistance to Change

Healthcare is a traditionally slow-to-adopt new technologies sector. Clinicians and staff might resist changing workflows and integrating new interoperability solutions. Fear of disruption to daily routines and potential compatibility issues can create inertia and slow down implementation. Additionally, the complexity of interoperability projects often exceeds stakeholders’ technical proficiency, contributing to resistance and skepticism. Overcoming resistance to change requires comprehensive stakeholder engagement, training programs, and clear communication about the benefits of interoperability for patient care and organizational efficiency.

Limited IT Expertise

Many healthcare providers lack the in-house IT expertise needed to effectively manage and maintain interoperability solutions. This can lead to implementation challenges, security vulnerabilities, and difficulties integrating with existing systems. Outsourcing IT services may alleviate some of these challenges, but it adds to the overall cost of interoperability initiatives. Healthcare organizations must invest in training and professional development programs to build internal IT capabilities and ensure the successful implementation and sustainability of interoperability solutions.

Consolidation in the Healthcare Industry

Mergers and acquisitions within the healthcare industry can create compatibility issues when different systems need to be integrated. This consolidation can also lead to a rise in the bargaining power of large vendors, potentially driving up costs for interoperability solutions. Healthcare organizations must navigate complex vendor relationships and negotiate interoperability agreements that meet their needs while mitigating cost escalation risks. Moreover, consolidation may exacerbate interoperability challenges by limiting competition and innovation in the healthcare IT market. Effective regulatory oversight and antitrust measures are essential to promote competition and ensure interoperability solutions remain accessible and affordable for all stakeholders.

Market Trends

Rising Awareness and Screening Rates

One of the primary market trends propelling the growth of the colorectal cancer screening and diagnostic market is the increasing awareness among the public regarding colorectal cancer and the crucial role of early detection. For instance, colorectal cancer is the third most common cancer worldwide, accounting for approximately 10% of all cancer cases and is the second leading cause of cancer-related deaths worldwide. Furthermore, recommendations from major health organizations, such as the American Cancer Society’s recent suggestion to lower the starting age for screenings from 50 to 45 years old, have further encouraged individuals to participate in screening programs. As a result, there has been a notable increase in the number of people undergoing colorectal cancer screening, with about 7 in 10 U.S. adults aged 50 to 75 being up-to-date with colorectal cancer screening.

Technological Advancements in Screening and Diagnostics

The continuous advancements in screening and diagnostic technologies play a pivotal role in driving market growth. Non-invasive and minimally invasive screening methods, such as stool DNA tests and colonoscopies with virtual colonoscopy technology, are gaining popularity due to their convenience and reduced discomfort for patients. For example, stool DNA tests have shown a sensitivity of 93.9% and a specificity of 90.6% for colorectal cancer. Virtual colonoscopy, also known as CT colonoscopy, has shown a sensitivity of about 96% for colorectal cancer. These innovations not only encourage greater participation in screening programs but also enhance the accuracy of cancer detection. High-resolution imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI) have made possible a faster and more robust imaging technique and the generation of new data of tumor phenotype.

Focus on Early Detection and Personalized Medicine

There is a notable shift in focus towards the early detection of colorectal cancer, as it is widely recognized that early-stage diagnosis significantly improves patient survival rates. Healthcare providers are increasingly emphasizing the importance of identifying colorectal cancer at its earliest stages through regular screening programs. Additionally, the rise of personalized medicine has revolutionized cancer treatment by allowing for the customization of treatment plans based on the specific genetic makeup of a patient’s tumor. This tailored approach not only maximizes treatment efficacy but also minimizes adverse effects, thereby enhancing patient care and outcomes.

Growing Adoption of Telehealth

The adoption of telehealth services has surged in recent years, particularly in the wake of the COVID-19 pandemic, making healthcare more accessible and convenient for patients. Telehealth platforms enable individuals to consult with healthcare providers remotely, discuss screening options, and receive guidance on preventive measures. This increased accessibility to healthcare services, including colorectal cancer screening consultations, has the potential to improve screening rates, particularly in underserved areas where access to traditional healthcare facilities may be limited. As telehealth continues to evolve and expand, its role in facilitating colorectal cancer screening and diagnostics is expected to grow further, driving market growth in the coming years.

Increasing Government Support and Reimbursement

Governments worldwide are recognizing the importance of colorectal cancer screening and diagnostics in reducing the burden of the disease and improving public health outcomes. As a result, many governments are implementing policies to promote colorectal cancer screening, raising public awareness, and expanding access to screening programs. Furthermore, governments are providing reimbursement for screening procedures, incentivizing healthcare providers to offer screening services and ensuring affordability for patients. This strong government support is expected to fuel market growth by facilitating widespread adoption of screening initiatives and improving overall healthcare accessibility and affordability for individuals at risk of colorectal cancer.

Market Restraints and Challenges

Limited Accessibility and Awareness:

Disparities in access to healthcare persist, particularly in underserved communities, leading to lower screening rates among certain demographics. Lack of awareness about colorectal cancer, available screening options, and the significance of early detection further exacerbates this issue. Addressing these disparities and enhancing awareness through targeted educational campaigns are essential to improving screening rates and reducing colorectal cancer mortality.

Cost Concerns and Reimbursement Issues:

The cost of screening procedures, particularly colonoscopies, poses a significant barrier for individuals, especially those without adequate health insurance coverage. Furthermore, complexities in insurance reimbursement for screening tests can create confusion and discourage participation. Healthcare systems must work towards reducing the financial burden associated with colorectal cancer screening by implementing cost-effective screening programs and streamlining reimbursement processes to improve accessibility for all individuals.

Patient Discomfort and Adherence:

Certain screening methods, such as colonoscopies, may induce discomfort or anxiety in patients due to their invasive nature. This discomfort can deter individuals from undergoing screening, leading to missed opportunities for early detection. Additionally, adherence to stool-based testing procedures, despite their non-invasive nature, can be challenging for some patients, impacting the effectiveness of these tests. Healthcare providers should prioritize patient comfort and develop strategies to improve adherence to screening protocols, thereby enhancing the efficacy of colorectal cancer screening programs.

Healthcare Provider Shortage:

A shortage of qualified healthcare providers, particularly gastroenterologists trained to perform colonoscopies, contributes to limited access to diagnostic procedures. This shortage results in longer wait times for screening appointments and delays in diagnosis, potentially compromising patient outcomes. Addressing the healthcare provider shortage through workforce development initiatives and incentivizing medical professionals to specialize in gastroenterology is critical to improving access to timely colorectal cancer screening and diagnosis.

Stigma Associated with Colorectal Cancer:

Social stigma surrounding colorectal cancer and screening procedures, particularly colonoscopies, can deter individuals from seeking necessary care. Overcoming this stigma requires targeted efforts to destigmatize colorectal cancer and promote the importance of screening in preventing and detecting the disease at an early stage. Healthcare providers and advocacy groups play a crucial role in challenging misconceptions and fostering a supportive environment for individuals undergoing colorectal cancer screening.

Data Privacy Concerns:

As the use of genetic testing and personalized medicine expands in colorectal cancer management, concerns about data privacy and security of sensitive patient information become increasingly pertinent. Healthcare organizations must prioritize data privacy measures to safeguard patient confidentiality and ensure compliance with regulatory requirements. This includes implementing robust encryption protocols, access controls, and data governance frameworks to mitigate the risk of data breaches and unauthorized access to patient information. Addressing data privacy concerns is essential to building trust among patients and promoting the widespread adoption of genetic testing and personalized medicine in colorectal cancer care.

Key Players

Recent Developments

In February 2024, Exact Sciences Corporation announced its strategic initiative to launch a new slate of assays over the coming years, marking a significant advancement in the field of colorectal cancer screening. Among these assays is an updated version of its renowned stool-based colorectal cancer screening test, Cologuard, which is poised to further enhance its effectiveness in detecting the disease. Additionally, Exact Sciences Corporation plans to introduce a complementary blood-based assay and a novel test for minimal residual disease detection, underscoring its commitment to improving early detection and treatment monitoring of colorectal cancer.

In  February 2024, Freenome Holdings, Inc. revealed a substantial achievement by securing $254 million in a new funding round, with Swiss pharmaceutical giant Roche leading the investment. This substantial funding injection will fuel Freenome’s efforts to develop innovative tests capable of detecting multiple early-stage cancers. Of particular note is Freenome’s focus on developing screening tests tailored for colorectal and lung cancers, demonstrating a proactive approach towards addressing two of the most prevalent and deadly forms of cancer worldwide.

In May 2023, Guardant Health, a leader in liquid biopsy technology, embarked on a collaboration with the Ohio State University Comprehensive Cancer Center to delve into colorectal cancer screening adherence. This partnership signifies Guardant Health’s commitment to advancing research efforts aimed at improving screening participation rates and ultimately reducing colorectal cancer mortality.

In  May 2023, Guardant Health took a significant step forward by submitting a premarket approval application to the U.S. Food and Drug Administration for its Shield blood test. This milestone underscores Guardant Health’s dedication to obtaining regulatory approval for its innovative liquid biopsy technology, which has the potential to revolutionize cancer detection and monitoring.

In April 2023, Mainz Biomed announced a strategic collaboration with the Instituto de Microecologia, signaling its intent to expand the commercial reach of ColoAlert, a colorectal cancer screening product, in both Spain and Portugal. This collaboration highlights Mainz Biomed’s commitment to leveraging partnerships to broaden the accessibility of its innovative screening solutions and improve colorectal cancer detection rates in the region.

In  May 2023, Olympus Corporation introduced the CF-HQ1100DL/I colon videoscope, a state-of-the-art device specifically designed for comprehensive inspection of the lower digestive system. This latest addition to Olympus’s product portfolio enhances its offerings in the colorectal cancer screening and diagnostics sector, reaffirming the company’s dedication to providing healthcare professionals with cutting-edge tools to improve patient care and outcomes.

Regional Analysis

North America

North America dominates the global colorectal cancer screening and diagnostic market, accounting for over 40% of the total market share. The United States drives this dominance, boasting advanced healthcare infrastructure, favorable reimbursement policies, and high awareness of colorectal cancer screening. The widespread adoption of screening tests, such as colonoscopy, fecal immunochemical tests (FIT), and stool DNA tests, has significantly contributed to the region’s market growth. Furthermore, the presence of key players, including Exact Sciences Corporation, Epigenomics AG, and QIAGEN N.V., has fostered innovation and the development of cutting-edge diagnostic technologies in this region.

Europe

Europe holds a substantial share of the colorectal cancer screening and diagnostic market, capturing approximately 30% of the global revenue. Countries like Germany, France, and the United Kingdom have well-established screening programs and high awareness of colorectal cancer prevention. The region’s market growth is driven by the increasing adoption of non-invasive screening tests, such as FIT and stool DNA tests, which offer convenience and improved patient compliance. Additionally, the presence of stringent regulations and guidelines for colorectal cancer screening has further propelled the market’s expansion in Europe.

Asia Pacific

The Asia Pacific region is experiencing rapid growth in the colorectal cancer screening and diagnostic market, with a market share of around 20%. Countries like China, Japan, and India are witnessing a surge in colorectal cancer cases, prompting healthcare authorities to implement screening programs and raise awareness. The region’s vast population and improving healthcare infrastructure have created lucrative opportunities for market players. Moreover, the increasing disposable income and adoption of Western lifestyles have contributed to the rising demand for advanced diagnostic technologies in this region.

Latin America

Latin America accounts for a modest share of the colorectal cancer screening and diagnostic market, estimated at around 6%. However, the region is anticipated to witness substantial growth in the coming years due to the rising prevalence of colorectal cancer and the implementation of national screening programs. Countries like Brazil and Mexico are leading the way in promoting colorectal cancer screening and investing in advanced diagnostic technologies. Additionally, the presence of favorable government initiatives and increasing healthcare expenditure are expected to drive market growth in the region.

Middle East and Africa

The Middle East and Africa region holds the smallest share of the colorectal cancer screening and diagnostic market, accounting for approximately 4% of the global revenue. Limited access to healthcare services, lack of awareness, and insufficient screening programs have hindered market growth in this region. However, initiatives by healthcare organizations and governments to improve cancer care and promote early detection are expected to create growth opportunities in the future. Countries like Saudi Arabia and the United Arab Emirates are leading the way in adopting advanced diagnostic technologies for colorectal cancer screening.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Future Outlook

  1. Continued Technological Advancements: Expect ongoing innovations in screening technologies, including non-invasive and molecular diagnostic methods, enhancing accuracy and patient comfort.
  2. Increasing Adoption of Personalized Medicine: Anticipate a rise in personalized treatment approaches based on individual genetic profiles, optimizing therapeutic outcomes for colorectal cancer patients.
  3. Enhanced Access to Screening: Efforts to improve accessibility through telehealth services and community-based screening programs will expand screening participation, particularly in underserved areas.
  4. Emphasis on Early Detection: With growing recognition of the importance of early diagnosis, initiatives promoting regular screenings and lowering age thresholds for screening eligibility will gain traction.
  5. Expansion of Liquid Biopsy Technology: Expect continued development and commercialization of liquid biopsy tests for colorectal cancer detection, offering convenient and non-invasive screening options.
  6. Regulatory Advances: Anticipate regulatory approvals for new screening technologies and assays, facilitating their integration into routine clinical practice and enhancing market growth.
  7. Integration of Artificial Intelligence (AI): The integration of AI algorithms into screening and diagnostic platforms will streamline data analysis, leading to improved accuracy and efficiency in colorectal cancer detection.
  8. Rising Healthcare Expenditure: Increasing healthcare spending globally will support investments in colorectal cancer screening infrastructure and initiatives, driving market expansion.
  9. Collaborative Research Efforts: Collaborations between industry stakeholders and research institutions will fuel innovation and accelerate the development of novel screening modalities and diagnostic tools.
  10. Heightened Awareness and Education: Continued efforts to raise public awareness about colorectal cancer and the importance of screening will promote early detection and improve patient outcomes.

1. Introduction
1.1. Report Description
1.2. Purpose of the Report
1.3. USP & Key Offerings
1.4. Key Benefits for Stakeholders
1.5. Target Audience
1.6. Report Scope
1.7. Regional Scope
2. Scope and Methodology
2.1. Objectives of the Study
2.2. Stakeholders
2.3. Data Sources
2.3.1. Primary Sources
2.3.2. Secondary Sources
2.4. Market Estimation
2.4.1. Bottom-Up Approach
2.4.2. Top-Down Approach
2.5. Forecasting Methodology
3. Executive Summary
4. Market Dynamics
4.1. Overview
4.2. Key Industry Trends
5. Colorectal Cancer Screening and Diagnostic Market Analysis
5.1. Market Overview
5.2. Market Performance
5.3. Impact of COVID-19
5.4. Market Forecast
6. Market Breakup by Type
6.1. Stool-based
6.1.1. Market Trends
6.1.2. Market Forecast
6.2. Fecal Immunochemical Test (FIT)
6.2.1. Market Trends
6.2.2. Market Forecast
6.3. Fecal Occult Blood Test (FOBT)
6.3.1. Market Trends
6.3.2. Market Forecast
6.4. Stool-DNA Test
6.4.1. Market Trends
6.4.2. Market Forecast
6.5. Colonoscopy
6.5.1. Market Trends
6.5.2. Market Forecast
6.6. Others
6.6.1. Market Trends
6.6.2. Market Forecast
7. Market Breakup by End-user
7.1. Hospitals & Clinics
7.1.1. Market Trends
7.1.2. Market Forecast
7.2. Clinical Laboratories
7.2.1. Market Trends
7.2.2. Market Forecast
7.3. Diagnostics Imaging Centers
7.3.1. Market Trends
7.3.2. Market Forecast
7.4. Others
7.4.1. Market Trends
7.4.2. Market Forecast
8. Market Breakup by Region
8.1. North America
8.1.1. Market Trends
8.1.2. Market Forecast
8.2. Europe
8.2.1. Market Trends
8.2.2. Market Forecast
8.3. Asia-Pacific
8.3.1. Market Trends
8.3.2. Market Forecast
8.4. Latin America
8.4.1. Market Trends
8.4.2. Market Forecast
8.5. Middle East and Africa
8.5.1. Market Trends
8.5.2. Market Forecast
9. SWOT Analysis
9.1. Overview
9.2. Strengths
9.3. Weaknesses
9.4. Opportunities
9.5. Threats
10. Value Chain Analysis
11. Porters Five Forces Analysis
11.1. Overview
11.2. Bargaining Power of Buyers
11.3. Bargaining Power of Suppliers
11.4. Degree of Competition
11.5. Threat of New Entrants
11.6. Threat of Substitutes
12. Price Analysis
13. Competitive Landscape
13.1. Market Structure
13.2. Key Players
13.3. Profiles of Key Players
13.3.1. NOVIGENIX SA (Switzerland)
13.3.1.1. Company Overview
13.3.1.2. Product Portfolio
13.3.2. EIKEN CHEMICAL CO., LTD. (Japan)
13.3.2.1. Company Overview
13.3.2.2. Product Portfolio
13.3.3. Clinical Genomics Technologies Pty Ltd. (U.S.)
13.3.3.1. Company Overview
13.3.3.2. Product Portfolio
13.3.4. Exact Sciences Corporation (U.S.)
13.3.4.1. Company Overview
13.3.4.2. Product Portfolio
13.3.5. Epigenomics AG (Germany)
13.3.5.1. Company Overview
13.3.5.2. Product Portfolio
13.3.6. bioMérieux, Inc. (France)
13.3.6.1. Company Overview
13.3.6.2. Product Portfolio
13.3.7. Olympus Corporation (Japan)
13.3.7.1. Company Overview
13.3.7.2. Product Portfolio
13.3.8. KARL STORZ SE & Co. KG (Germany)
13.3.8.1. Company Overview
13.3.8.2. Product Portfolio
13.3.9. FUJIFILM Holdings America Corporation (Japan)
13.3.9.1. Company Overview
13.3.9.2. Product Portfolio

Frequently Asked Questions:

What is the projected growth of the Colorectal Cancer Screening and Diagnostic Market between 2023 and 2032?

The Colorectal Cancer Screening and Diagnostic Market is projected to experience substantial growth, with its value expected to surge from USD 15,967.68 million in 2023 to USD 31,702.6 million by 2032, reflecting a notable CAGR of 8.83%.

What factors are driving the growth of the Colorectal Cancer Screening and Diagnostic Market?

Market dynamics are chiefly influenced by the increasing global incidence of colorectal cancer, driven by factors such as aging populations, sedentary lifestyles, and dietary habits. Additionally, growing awareness campaigns and government initiatives promoting early detection have spurred market growth. Advancements in screening technologies and diagnostic modalities have also revolutionized colorectal cancer management.

Who are the major players in the Colorectal Cancer Screening and Diagnostic Market?

Major players in the Colorectal Cancer Screening and Diagnostic Market include NOVIGENIX SA (Switzerland), EIKEN CHEMICAL CO., LTD. (Japan), Clinical Genomics Technologies Pty Ltd. (U.S.), Exact Sciences Corporation (U.S.), Epigenomics AG (Germany), bioMérieux, Inc. (France), Olympus Corporation (Japan), KARL STORZ SE & Co. KG (Germany), and FUJIFILM Holdings America Corporation (Japan).

How is the availability of Colorectal Cancer Screening and Diagnostic Market expanding, and through what channels?

The availability of colorectal cancer screening and diagnostic services is expanding through various channels, including hospitals, clinics, clinical laboratories, and diagnostic imaging centers. These healthcare facilities offer a diverse range of screening and diagnostic tools, catering to the needs of patients across different regions. Additionally, advancements in telehealth services have further expanded access to screening consultations and discussions with healthcare providers remotely, improving accessibility for individuals in underserved areas.

Small Animal Respiratory Diseases Treatment Market

Published:
Report ID: 10022

AI in Vitro Diagnostics Market

Published:
Report ID: 39163

U.S. 503b Compounding Pharmacies Market

Published:
Report ID: 15988

UAE Minimally Invasive Biopsy Techniques Market

Published:
Report ID: 38790

Saudi Arabia Minimally Invasive Biopsy Technique Market

Published:
Report ID: 38766

Lung Cancer Therapeutics Market

Published:
Report ID: 38769

Breast Cancer Market

Published:
Report ID: 38761

Positive Patient Identification (PPID) Market

Published:
Report ID: 10622

Inflation Devices Market

Published:
Report ID: 38697

Microbiology Culture Market

Published:
Report ID: 38672

Medical Processing Seals Market

Published:
Report ID: 38667

Egypt In-Vitro Fertilization (IVF) Market

Published:
Report ID: 38526

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN